Insufficient cerebrospinal fluid penetration of tedizolid: a case report
Xavier Brousse1,2, Minh P Lê3,4, Marin Lahouati5
1Infectious Diseases Unit, University Hospital of La Réunion, Saint-Pierre, Reunion Island 97410, France.
Purpose:
Tedizolid, a novel oxazolidinone developed for the treatment of skin and soft tissue infections, exhibits a longer half-life than linezolid, with reduced myelosuppression and neurotoxicity. However, its penetration into the cerebrospinal fluid (CSF) remains poorly characterized. Our case report evaluated the CSF penetration of tedizolid.
Case Presentation:
We present a case of parameningeal aseptic meningitis secondary to otogenic skull base osteomyelitis. Tedizolid concentrations in CSF and serum were measured using liquid chromatography and tandem mass spectrometry. The trough CSF concentration of tedizolid was below the limit of quantification, whereas the corresponding serum concentration was within the expected therapeutic range. A brief review of the literature corroborated the observation that CSF penetration of tedizolid was markedly lower than that of linezolid.
Conclusion:
Considering the consistently low CSF concentrations of tedizolid, linezolid remains the preferred agent for the treatment of CNS infections.
